GRI Bio, Inc. 8-K

What Happened

• GRI Bio, Inc. filed a Current Report on Form 8‑K dated May 14, 2026 to furnish a press release announcing its financial results for the three months ended March 31, 2026. The press release is attached as Exhibit 99.1.
• The filing also incorporates by reference the press release section titled “Phase 2a Data – GRI‑0621 in IPF,” making those trial results part of the 8‑K disclosure. The report is signed by CFO Leanne Kelly.

Key Details

• Filing date: May 14, 2026 (Form 8‑K furnished to report Q1 results).
• Reporting period: Three months ended March 31, 2026 (quarterly results/earnings disclosed in the press release).
• Exhibit included: Exhibit 99.1 = Press Release (contains financial results and Phase 2a GRI‑0621 IPF data).
• Authorized signature: Leanne Kelly, Chief Financial Officer.

Why It Matters

• The 8‑K signals that GRI Bio has publicly released its quarterly earnings and operational highlights; investors should read Exhibit 99.1 for the specific revenue, expense, net loss/profit and other financial metrics that can affect valuation.
• Incorporation of the “Phase 2a Data – GRI‑0621 in IPF” means trial data for GRI‑0621 are formally disclosed in this filing—important clinical progress information for biotech investors evaluating the company’s pipeline and risk profile.
• Retail investors should review the press release (Exhibit 99.1) for the detailed numbers and clinical results and monitor subsequent filings or presentations for further financial detail and clinical context.